C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells
Journal of Allergy and Clinical Immunology · 2023
DOI: 10.1016/j.jaci.2023.06.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023. Verfasst von Alona A Merkulova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Division, Department of Medicine, Case Western Reserve University, Cleveland, Ohio. Hauptthemen laut MEDLINE: Prekallikrein, Factor XII. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: We examined how prekallikrein (PK) activation on human microvascular endothelial cells (HMVECs) is regulated by the ambient concentration of C1 inhibitor (C1INH) and prolylcarboxypeptidase (PRCP). OBJECTIVE: We sought to examine the specificity of PK activation on HMVECs by PRCP and the role of C1INH to regulate it, high-molecular-weight kininogen (HK) cleavage, and bradykinin (BK) liberation. METHODS: Investigations were performed on cultured HMVECs. Immunofluorescence, enzymatic activity assays, immunoblots, small interfering RNA knockdowns, and cell transfections were used to perform these studies. RESULTS: Cultured HMVECs constitutively coexpressed PK, HK, C1INH, and PRCP. PK activation on HMVECs was modulated by the ambient C1INH concentration. In the absence of C1INH, forming PKa on HMVECs cleaved 120-kDa HK completely to a 65-kDa H-chain and a 46-kDa L-chain in 60 minutes. In the presence of 2 μM C1INH, only 50% of the HK became cleaved. C1INH concentrations (0.0-2.5 μM) decreased but did not abolish BK liberated from HK by activated PK. Factor XII did not activate when incubated with HMVECs alone for 1 hour. However, if incubated in the presence of HK and PK, factor XII became activated. The specificity of PK activation on HMVECs by PRCP was shown by several inhibitors to each enzyme. Furthermore, PRCP small interfering RNA knockdowns magnified C1INH inhibitory activity on PK activation, and PRCP transfections reduced C1INH inhibition at any given concentration. CONCLUSIONS: These combined studies indicated that on HMVECs, PK activation and HK cleavage to liberate BK were modulated by the local concentrations of C1INH and PRCP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Oncology Division, Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
- Hematology and Oncology Division, Department of Medicine, Case Western Reserve University, Cleveland, Ohio; University Hospitals Cleveland Medical Center, Cleveland, Ohio.
- Hematology and Oncology Division, Department of Medicine, Case Western Reserve University, Cleveland, Ohio; University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address: Schmaier@case.edu.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Merkulova, A. A., Abdalian, S., Silbak, S., Pinheiro, A., & Schmaier, A. H. (2023). C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.06.017
Vancouver
Merkulova AA, Abdalian S, Silbak S, Pinheiro A, Schmaier AH. C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.06.017
BibTeX
@article{Merkulova2023,
author = {Merkulova, Alona A and Abdalian, Sarah and Silbak, Sadiq and Pinheiro, Alessandro and Schmaier, Alvin H},
title = {C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
doi = {10.1016/j.jaci.2023.06.017}
}
EUVIMED